Drug trial aims to halt devastating nerve attacks
NCT ID NCT06673394
Summary
This study aimed to see if the drug eculizumab could quickly reduce disability during sudden, severe attacks of neuromyelitis optica spectrum disorder (NMOSD). It planned to test this in adults who tested positive for a specific antibody and were having a new attack affecting their vision or spinal cord. The trial was designed as an open-label Phase 2 study but was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.